Teva- Pharmaceutical Industries Ltd (TEVA)

NYSE · Healthcare · Drug Manufacturers - Specialty & Generic · Israel

Teva- Pharmaceutical Industries Ltd is a large cap company (market value between $10 billion and $200 billion) in the Drug Manufacturers - Specialty & Generic industry.

Teva is a biopharmaceutical company that develops, manufactures and sells generic medicines, biosimilars, innovative medicines and over-the-counter products worldwide. The company operates through three regional segments: United States, Europe and International Markets, serving retail drug chains, wholesalers, hospitals and pharmacies.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the Teva- Pharmaceutical Industries Ltd stock.

Our verdict on TEVA

Overvalued: intrinsic value $20.28 per share, market price $42.62, margin of safety -110.1% (as of 2026-11-17).

Discounting its cash flows at 9.7% (average of 3 methods) values the shares at $20.28; the price of $42.62 is 110% above that value, and 73% of that value comes from beyond year five.

ETFs with the most weight in TEVA

More on TEVA

Browse

Peers in Drug Manufacturers - Specialty & Generic

All 82 Drug Manufacturers - Specialty & Generic stocks

Compare side by side

Cheaper than TEVA in Drug Manufacturers - Specialty & Generic

22 more in this industry show a wider margin of safety.

Is TEVA undervalued or overvalued?

TEVA is overvalued (as of the 2026-11-17 close). Discounting its cash flows at 9.7% (average of 3 methods) values the shares at $20.28; the price of $42.62 is 110% above that value, and 73% of that value comes from beyond year five.

What is the intrinsic value of TEVA?

$20.28 per share (as of the 2026-11-17 close), against a market price of $42.62. That is a margin of safety of -110.1%. The value is the average of the 3 valuation methods that apply to this company, recomputed every night after the US close.